Invion Ownership
| IVIXF Stock | USD 0.04 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Invion |
Invion Pink Sheet Ownership Analysis
About 47.0% of the company shares are held by company insiders. The book value of Invion was currently reported as 0.0. The company had not issued any dividends in recent years. Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company was incorporated in 2000 and is headquartered in Melbourne, Australia. Invion operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.The quote for Invion Limited is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Invion Limited call the company at 61 3 9692 7222 or check out https://www.inviongroup.com.Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Invion Pink Sheet
Invion financial ratios help investors to determine whether Invion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Invion with respect to the benefits of owning Invion security.